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Tafasitamab (MOR208), an Fc-modified, humanized, anti-CD19 monoclonal antibody, combined with the immunomodulatory drug lenalidomide was clinically active with a good tolerability 
profile in the open-label, single-arm, phase II L-MIND study of patients 
with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) ineligi-
ble for autologous stem-cell transplantation. To assess long-term out-
comes, we report an updated analysis with ≥35 months’ follow-up. 
Patients were aged >18 years, had received one to three prior systemic 
therapies (including ≥1 CD20-targeting regimen) and Eastern 
Cooperative Oncology Group performance status 0-2. Patients received 
28-day cycles of tafasitamab (12 mg/kg intravenously), once weekly dur-
ing cycles 1-3, then every 2 weeks during cycles 4-12. Lenalidomide (25 
mg orally) was administered on days 1-21 of cycles 1-12. After cycle 12, 
progression-free patients received tafasitamab every 2 weeks until dis-
ease progression. The primary endpoint was best objective response 
rate. After ≥35 months’ follow-up (data cut-off: October 30, 2020), the 
objective response rate was 57.5% (n=46/80), including a complete 
response in 40.0% of patients (n=32/80) and a partial response in 17.5% 
of patients (n=14/80). The median duration of response was 43.9 months 
(95% confidence interval [95% CI]: 26.1-not reached), the median over-
all survival was 33.5 months (95% CI: 18.3-not reached) and the median 
progression-free survival was 11.6 months (95% CI: 6.3-45.7). There 
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Introduction 
Diffuse large B-cell lymphoma (DLBCL) is the most 
common subtype of non-Hodgkin lymphoma, account-
ing for 25-45% of new cases of lymphoma each year.1  
The introduction of rituximab treatment, an anti-CD20 
antibody, alongside cyclophosphamide, doxorubicin, 
prednisone, and vincristine (R-CHOP) as an initial stan-
dard-of-care immunotherapy has improved patients’ out-
comes; however, 30–40% of patients continue to experi-
ence relapse or are refractory to this first-line therapy.2 For 
these relapsed or refractory (R/R) patients, alternative 
effective and tolerable treatment options are limited and, 
thus, their prognosis is poor.2 
Current treatment options for R/R DLBCL include sal-
vage chemotherapy followed by high-dose chemothera-
py and autologous stem-cell transplantation (ASCT).3,4 
However, the majority of patients with R/R DLBCL who 
undergo ASCT subsequently relapse.2 More recently-
developed therapies, such as chimeric antigen receptor 
(CAR) T-cell therapy and the antibody-drug conjugate 
polatuzumab vedotin in combination with bendamustine 
and rituximab, have shown improved patients’ 
outcomes.5-7 However, CAR T-cell therapies have been 
associated with severe adverse events, including grade ≥3 
cytokine release syndrome and neurotoxicity, and some 
can be difficult to administer safely and successfully.5,6 
Thus, there remains an urgent need for novel, tolerable, 
and easy-to-administer treatment options for patients 
with R/R DLBCL, particularly those ineligible for ASCT. 
The combination of tafasitamab (MOR208, previously 
XmAb5574), an Fc-modified, humanized anti-CD19 
monoclonal antibody, with lenalidomide has been shown 
to be effective and well-tolerated in patients with R/R 
DLBCL who are ineligible for ASCT.8 The phase II study, 
L-MIND, demonstrated an objective response rate of 
60%, with 43% of patients achieving a complete 
response (CR).8 Moreover, the responses were durable, 
with a median duration of response (DoR) of 21.7 
months.8 To further determine the long-term clinical effi-
cacy and safety of tafasitamab plus lenalidomide treat-
ment in patients with R/R DLBCL, we provide updated 
data based on a minimum follow-up of 35 months. 
Additionally, to understand the effectiveness of this novel 
treatment regimen in clinically relevant subgroups of 
patients, we present long-term efficacy analyses stratified 






L-MIND was an open-label, single-arm, multicenter, phase II 
study (NCT02399085).8 The study was approved by the institu-
tional review boards at each study site, and conducted in accor-
dance with International Council for Harmonization Good 
Clinical Practice guidelines and the Declaration of Helsinki; all 
patients provided written informed consent. We present data 
after 35 months of follow-up from the last patient enrolled. 
Study design and patients 
Details of the L-MIND study have been published elsewhere; 
eligibility criteria are further described in the Online 
Supplementary Methods.8 Patients with primary refractory disease 
were excluded, although until a protocol amendment in June 
2016, primary refractoriness was defined as no response or pro-
gressive disease (PD) within <3 months of frontline therapy, 
rather than 6 months. Therefore, prior to this amendment 
patients with relapse or PD 3-6 months from frontline therapy 
were included, and form a subgroup of ‘primary refractory 
patients’ as per B-cell lymphoma National Comprehensive 
Cancer Network guidelines.3 Patients with rituximab-refractory 
disease had no response to or PD following a rituximab-contain-
ing regimen within <6 months of completion of therapy. 
Patients received up to 12 cycles (28 days each) of tafasitamab 
and lenalidomide, followed by tafasitamab monotherapy in 
patients with stable disease or better, until PD. Tafasitamab (12 
mg/kg intravenously) was administered on days 1, 8, 15, and 22 
during cycles 1-3, with a loading dose on day 4 of cycle 1, and 
on days 1 and 15 from cycle 4 onwards. Lenalidomide (25 mg 
orally) was self-administered on days 1-21 of each 28-day cycle. 
For further details see the Online Supplementary Methods. 
Study outcomes 
The primary endpoint was the objective response rate (CR 
plus partial response [PR]), assessed by an independent review 
committee (IRC), according to the 2007 International Working 
Group response criteria for malignant lymphoma.9 Secondary 
endpoints included DoR (time from initial CR or PR to first 
observation of PD), progression-free survival (PFS; time from 
first dosing to lymphoma progression or death), overall survival 
(OS; time from first dosing to date of death), and incidence and 
severity of adverse events. Exploratory subgroup analyses were 
performed to evaluate DoR, PFS, and OS by refractoriness to 
prior treatment, as well as age, gender, International Prognostic 
Index (IPI) score, prior ASCT, and number of prior treatment 
lines. Rituximab refractoriness was defined as a response less 
than PR to any rituximab-containing regimen during the course 
of treatment or PD within ≤6 months of treatment completion. 
Refractoriness to last prior treatment and primary refractoriness 
were defined as a best response less than PR to the most recent 
therapy or to first-line treatment, respectively, or PD before or 
≤6 months after completion of that treatment. 
Statistical analyses 
The previously published primary analysis for the L-MIND 
study (data cut-off: November 30, 2018)8 was carried out when 
all patients had completed a minimum of 12 months’ follow-up. 
The data cut-off date for the present analyses was October 30, 
2020. The full analysis set comprised patients who received both 
tafasitamab and lenalidomide and was used to analyze efficacy 
outcomes. The safety analysis set comprised patients who 
received any study medication. 
were no unexpected toxicities. Subgroup analyses revealed consistent long-term efficacy results across 
most subgroups of patients. This extended follow-up of L-MIND confirms the long duration of response, 
meaningful overall survival, and well-defined safety profile of tafasitamab plus lenalidomide followed by 
tafasitamab monotherapy in patients with relapsed/refractory diffuse large B-cell lymphoma ineligible 
for autologous stem cell transplantation. ClinicalTrials.gov identifier: NCT02399085.
Results 
Patients 
Overall, 81 patients received at least one dose of either 
drug and were evaluated for safety. Of those, 80 patients 
received ≥1 dose of both tafasitamab and lenalidomide 
and were evaluated for efficacy (Figure 1). A total of 34 
patients received tafasitamab monotherapy after discon-
tinuing lenalidomide (30/34 patients had completed 12 
cycles of tafasitamab plus lenalidomide and 4/34 had dis-
continued lenalidomide prior to cycle 12 and continued 
tafasitamab). Fifteen of these 34 patients had discontin-
ued tafasitamab treatment at the data cut-off for this 
analysis; thus, 19 patients were still receiving tafasitamab 
monotherapy. Of the 62/81 patients who had discontin-
ued study treatment, 42 had died, 13 were alive and 
included in the survival follow-up and 7 had been lost to 
follow-up at the data cut-off for this report.  
The full baseline characteristics of the patients in the L-
MIND study have already been published.8 Briefly, the 
patients had a median age of 72 years (range, 41-86) at 
enrollment and had received a median of two (range, 1-4) 
prior lines of therapy. All patients had received R-CHOP 
or equivalent chemoimmunotherapy prior to study entry. 
With the availability of additional data from a central 
pathology review of two patients, the baseline patients’ 
characteristics for cell of origin by immunohistochem-
istry and gene expression profiling have been updated 
since the primary analysis (Table 1). There was one 
patient each with double- and triple-hit DLBCL. 
Patient subgroups of clinical interest included 15 
patients (18.5%) with primary refractory disease, 33 
patients (41.3%) with rituximab-refractory disease, and 
35 patients (43.8%) who were refractory to their last ther-
apy. Most patients who were refractory to their last line 
of therapy had received two prior lines of treatment 
(71.4%), and the last prior line included chemotherapy in 
94.4% and rituximab in 80.0% of cases. The baseline 
characteristics of patients in the refractory subgroups 
were generally comparable with those of the overall pop-
ulation (Table 1), although patients in refractory sub-
groups were more likely to have increased lactate dehy-
drogenase and germinal center B cell of origin by 
immunohistochemistry. 
Prior treatment regimens for patients refractory to their 
last treatment are shown in Online Supplementary Table S1.  
Efficacy outcomes 
After the primary analysis, the best responses for three 
patients were revised based on an IRC re-adjudication 
due to a disagreement between the two primary radiolo-
gists. At this long-term data cut-off after at least 35 
months’ follow-up, the IRC-assessed objective response 
rate was 57.5% (46/80; 95% confidence interval [95% 
CI]: 45.9-68.5), the CR rate was 40.0% (32/80) and the PR 
rate was 17.5% (14/80) (Table 2). Additionally, 16.3% of 
patients (13/80) had stable disease. The median time to 
response was 2.1 months (range, 1.7-34.7) and the medi-
an time to CR was 6.8 months (range, 1.7-46.3). Thirty 
patients had completed the combination treatment phase 
of 12 cycles on both study drugs and achieved a best 
response of CR (n=24), PR (n=3), or stable disease (n=3) 
as per IRC. 
Time-to-event endpoints are shown in Table 2 with 
Kaplan-Meier plots in Figure 2. The median IRC-assessed 
DoR was 43.9 months (95% CI: 26.1-not reached [NR]), 
and was not reached in patients who achieved a CR (95% 
CI: 43.9-NR). The median IRC-assessed PFS was 11.6 
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Figure 1. CONSORT (Consolidated Standards of Reporting Trials) diagram of the L-MIND study at the October 30, 2020 data cut-off.
months (95% CI: 6.3-45.7) with a median follow-up for 
PFS of 33.9 months. A total of 38 patients were censored 
at data cut-off; 21/38 patients (55.3%) were ongoing on 
PFS follow-up. The Kaplan-Meier plot of PFS suggests a 
plateau at around 18 months (Figure 2B). The median OS 
had not been reached at the primary analysis and was 
33.5 months (95% CI: 18.3-NR) in this analysis, with a 
median survival follow-up of 42.7 months. Figure 2C 
shows the impact of response quality on OS; among the 
patients with a CR, the median OS was not reached, and 
OS estimates were 96.9% (95% CI: 79.8-99.6) at 18 
months, 90.6% (95% CI: 73.7-96.9) at 24 months, and 
81.3% (95% CI: 62.9-91.1) at 36 months. Among patients 
with a PR, the median OS was 22.5 months (95% CI: 8.6-
NR), and OS estimates were 59.8% (95% CI: 28.5-81.0) at 
18 months, 42.7% (95% CI: 15.9-67.5) at 24 months and 
34.2% (95% CI: 10.7-59.8) at 36 months. In patients who 
received tafasitamab plus lenalidomide as second-line 
treatment (n=40), the median PFS was 23.5 months (95% 
CI: 7.4-NR), the median DoR was 43.9 months (95% CI: 
9.1-NR) and the median OS was 45.7 (95% CI: 24.6-NR). 
In patients receiving tafasitamab plus lenalidomide as 
third- or later-line treatment (n=40), the median PFS was 
7.6 months (95% CI: 2.7-NR), the median DoR was not 
reached (95% CI: 15.0-NR) and the median OS was 15.5 
months (95% CI: 8.6-NR). 
Following the discontinuation of treatment in L-MIND, 
33 patients received subsequent salvage therapies, which 
included stem cell transplant in two patients and CAR T-
cell therapy in two other patients, following further 
chemotherapy (see Online Supplementary Results). 
Additionally, five patients who achieved a CR in L-MIND 
but discontinued the treatment for reasons other than dis-
ease progression were alive at the data cut-off date for 
this analysis, without further therapeutic intervention. 
Subgroup analyses 
Overall response and CR rates were consistent regard-
less of refractoriness in patient subgroups of clinical inter-
est although, as expected, the median PFS and OS were 
short in patients with primary refractory disease (5.3 
months and 13.8 months, respectively), rituximab-refrac-
tory and last-line refractory disease (both 7.6 months and 
15.5 months, respectively) (Table 2). Forest plots for 
Kaplan-Meier estimates of 30-month time-to-event end-
points are shown in Figure 3. Across DoR, PFS and OS, 
the only patient subgroup that consistently had a signifi-
cantly poorer prognosis than the overall group was that 
of patients with an intermediate-high and high-risk IPI 
score. Patients in the rituximab-refractory (n=33 evalu-
able) and last-line-refractory (n=35 evaluable) subgroups 
had similar 30-month DoR and PFS rates to the rest of the 
population (DoR: 66.2% vs. 65.5% and 57.7% vs. 69.5%; 
PFS: 40.0% vs. 42.6% and 37.2% vs. 44.2%, respectively), 
whereas 30-month DoR and PFS rates were lower in 
patients with primary refractory disease (n=15; DoR: 
50.0% vs. 66.7%; PFS: 33.9% vs. 42.3%) (Figure 3A, B). In 
all refractory subgroups, the 30-month OS rate was lower 
compared with that of the rest of the population (Figure 
3C). Kaplan-Meier plots for PFS in the refractory sub-
groups are shown in Online Supplementary Figure S1. 
Based on medical history and central pathology diagno-
sis, eight patients had DLBCL arising from transformation 
of low-grade lymphoma, and there was one patient each 
with double- and triple-hit lymphoma. Of the eight 
patients with transformed lymphoma, four experienced 
PR, three experienced CR and one had stable disease as 
best response. The patient with double-hit lymphoma 
(MYC and BCL2 translocations) was refractory to his last 
line of therapy before L-MIND (rituximab-dexametha-
sone-cytarabine-cisplatin) and achieved a PR to tafasitam-
ab and lenalidomide, and was progression-free for >6 
months. The patient with triple-hit lymphoma (MYC, 
BCL2 and BCL6 translocations) had previously experi-
enced a CR for 4.5 months in response to R-CHOP and 
started tafasitamab plus lenalidomide 1 month after 
relapse. This patient experienced a CR in L-MIND with 
sustained remission for >30 months. Swimmer plots for 
all of these patients are shown in Online Supplementary 
Figure S2.  
Safety outcomes 
As of October 30, 2020, the median duration of expo-
sure to study treatment (either lenalidomide or tafasitam-
ab) was 9.2 months (range, 0.2-54.7). The median dura-
tion of exposure to tafasitamab monotherapy (following 
J. Duell et al.
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Table 1. Updated baseline characteristics and patient subgroups of clinical 
interest. 
                                              All patients      Primary      Rituximab    Last therapy 
                                                                    refractory     refractory      refractory 
                                                                      disease         disease          disease 
 Number                                                 81                     15                     34                      36 
 Median age, years (range)       72 (41-86)      73 (48-82)     72.5 (41-82)    72.5 (41-82) 
 Age >70 years, n (%)                    45 (56)             9 (60)             19 (56)             20 (56) 
 Median prior lines                         2 (1-4)             2 (1-4)            2 (1-4)             2 (1-4) 
 of treatment (range) 
 Stage III/IV, n (%)                          61 (75)            10 (67)            24 (71)             27 (75) 
 Increased LDH, n (%)                  45 (56)            10 (67)            22 (65)             25 (69) 
 IPI 3-5, n (%)                                  41 (51)             8 (53)             19 (56)             21 (58) 
 Prior ASCT, n (%)                            9 (11)                   0                   3 (9)                4 (11) 
 Cell of origin (by IHC), n (%) 
     GCB                                               39 (48)            12 (80)            21 (62)             21 (58) 
     Non-GCB                                     22 (27)              1 (7)               6 (18)               8 (22) 
     Unknown                                     20 (25)             2 (13)              7 (21)               7 (19) 
 Cell of origin (by GEP), n (%) 
     GCB                                                8 (10)              2 (13)              5 (15)               5 (14) 
     ABC                                               20 (25)             5 (33)              8 (24)               8 (22) 
     Unclassified                                  6 (7)                1 (7)                1 (3)                4 (11) 
     Not evaluable                                5 (6)               2 (13)               3 (9)                 3 (8) 
     Missing                                         42 (52)             5 (33)             17 (50)             16 (44) 
 Patients with transformed  
 lymphoma,* n (%) 
    B-cell lymphoma                           4 (5)                1 (7)                2 (6)                 2 (3) 
    Marginal zone lymphoma            2 (3)                1 (7)                   0                     1 (3) 
    NHL unspecified histology         1 (1)                    0                       0                        0 
    Case reported by central            1 (1)                    0                       0                     1 (3) 
    pathology review                                
*Defined from records in the medical history for seven patients with transformed lymphoma 
and as a current medical condition (ongoing at cycle 1, day 1) for one B-cell lymphoma patient. 
Refractory subgroups may overlap. Primary refractory disease was defined as progression dur-
ing first-line treatment and/or progressive disease or stable disease as response to first-line treat-
ment or progressive disease within 6 months after completion of first-line treatment. Rituximab-
refractory disease was defined as progressive disease or stable disease in response to any ritux-
imab-containing regimen or progressive disease during or within 6 months of completion of any 
rituximab-containing therapy line. Last therapy-refractory disease was defined as progressive dis-
ease or stable disease in response to the most recently administered therapy before study entry. 
LDH: lactate dehydrogenase; IPI: International Prognostic Index; ASCT: autologous stem-cell 
transplant; IHC: immunohistochemistry; GCB: germinal center B cell; GEP:gene expression pro-
filing; ABC: activated B-cell; NHL: non-Hodgkin lymphoma. 
discontinuation of lenalidomide at any time [n=52]) was 
13.9 months (range, 0.2-43.4), compared with a median 
of 4.1 months’ exposure to tafasitamab monotherapy in 
the primary analysis (range, 0.1-20.8 months; data cut-off 
November 30, 2018).8 However, with the exception of 
one patient with recurrence of a previously diagnosed 
marginal zone lymphoma that was documented as an 
adverse event (Figure 1), no patients discontinued the 
study due to adverse events during the tafasitamab 
extended monotherapy phase.  
Overall, 64 (79.0%) patients required a temporary inter-
ruption of tafasitamab, of which 73.4% cases were due to 
adverse events. During combination therapy, 43 (53.1%) 
patients required no dose reduction of lenalidomide from 
the starting dose of 25 mg. Lenalidomide interruptions 
were required by 28 (34.6%) patients, being due to 
adverse events in 89.3% of cases, and 37 patients (45.7%) 
required a lenalidomide dose reduction. The most fre-
quent treatment-emergent adverse event (TEAE) leading 
to treatment interruption for tafasitamab (± lenalidomide) 
and lenalidomide (± tafasitamab) was neutropenia (28 
[34.6%] patients and 24 [29.6%] patients, respectively). 
During the extended tafasitamab monotherapy phase, 21 
(52.5%) patients had an interruption of tafasitamab treat-
ment due to at least one TEAE, the most common reasons 
being neutropenia or leukopenia (9 patients) and respira-
tory tract infections (6 patients). 
At the current analysis, 42 patients (51.9%) had died. 
There were eight deaths (9.9%) on treatment (5 related to 
PD, plus 1 stroke, 1 sudden death and 1 respiratory fail-
ure), and 34 deaths (42.0%) after treatment (26 related to 
PD, plus 1 intracerebral hemorrhage, 1 pulmonary edema 
due to heart failure, 1 pneumonia, 1 end-stage marrow 
failure, 1 progressive multifocal leukoencephalopathy, 1 
congestive heart failure and 1 acute myeloid leukemia 
considered by the investigator to be secondary to past 
chemotherapy, and 1 unknown cause).  
At a median follow-up for OS of 42.7 months, com-
pared with 19.6 months at the primary analysis (an addi-
tional follow-up duration of 23.1 months), TEAE were 
consistent in incidence and severity with the those of the 
primary analysis (Table 3), with the most common TEAE 
(all grades) at extended follow-up remaining neutropenia 
(51%) and anemia (37%). The adverse event burden, 
expressed in terms of number of adverse events per 
patient-year of exposure to study medication, decreased 
greatly during the tafasitamab monotherapy phase com-
pared with that during the combination therapy phase 
(Table 4). Consistent with the safety profile of tafasitam-
ab monotherapy in other studies,10,11 the most common 
adverse events during the monotherapy phase were neu-
tropenia, cough, diarrhea, anemia, nasopharyngitis, and 
pyrexia, and the majority of adverse events were of grade 
1 or 2. Similar to the primary analysis, the most common 
grade ≥3 TEAE were neutropenia (49%), thrombocytope-
nia (17%) and febrile neutropenia (12%). 
Treatment-emergent serious adverse events (SAE) were 
reported in 43 patients (53.1%). The most common SAE 
were pneumonia (7 patients [8.6%]), febrile neutropenia 
(5 patients [6.2%]), pulmonary embolism (3 patients 
[3.7%]), bronchitis, lower respiratory tract infection, atri-
al fibrillation and congestive cardiac failure (all 2 patients 
[2.5%]). Of these, pneumonia and lower respiratory tract 
infection had been reported in an additional two and one 
patients, respectively, compared with the primary analy-
sis, while the rest remained unchanged. Overall, ten 
patients (12.3%) experienced febrile neutropenia (grade 3 
or 4). Five of these patients also developed infections 
whose timing was associated with febrile neutropenia 
(urinary tract infection [grade 3 adverse event]; sepsis and 
urinary tract infection [both grade 4 SAE]; Enterobacter 
bacteremia [grade 3 SAE]; staphylococcal skin infection 
[grade 2 adverse event]; rhinitis [grade 1 adverse event] 
and respiratory syncytial virus infection [grade 3 SAE]), 
and all recovered within 3-24 days; the other five patients 
developed no infections at all or their timing was not 
associated with febrile neutropenia. 
Between the primary analysis and this update, there 
were few new adverse events reported related to infec-
tion and rash (Online Supplementary Table S2). This obser-
vation is consistent with the low incidence of these 
events associated with tafasitamab monotherapy. 
Eleven patients (13.6%) experienced 13 TEAE of special 
interest, including tumor flare (3 events in 3 patients 
[3.7%]), allergic dermatitis (3 events in 3 patients [3.7%]), 
basal cell carcinoma (4 events in 2 patients [2.5%]), 
myelodysplastic conditions (2 events in 2 patients 
[2.5%]), and Bowen disease (1 event in 1 patient [1.2%]). 
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Table 2. Efficacy outcomes in the primary and follow-up analyses. 
                                                              Tafasitamab plus lenalidomide (N=80)‡                          Clinically relevant subgroups (follow-up analysis) 
                                                             Primary analysis          Follow-up analysis        Primary refractory       Rituximab-refractory        Last-therapy- 
                                                                (data cut-off:                 (data cut-off:                    disease                          disease                     refractory  
                                                              Nov 30, 2018)8               Oct 30, 2020)                     (n=15)                            (n=33)                        (n=35) 
 Best objective response, n (%) 
     Complete response                                        34 (42.5)                              32 (40.0)                              5 (33.3)                               13 (39.4)                          14 (40.0) 
     Partial response                                              14 (17.5)                              14 (17.5)                              3 (20.0)                                5 (15.2)                            7 (20.0) 
     Stable disease                                                  11 (13.8)                              13 (16.3)                              2 (13.3)                                4 (12.1)                             3 (8.6) 
     Progressive disease                                        13 (16.3)                              13 (16.3)                              3 (20.0)                                7 (21.2)                            7 (20.0) 
     Not evaluable*                                                  8 (10.0)                                8 (10.0)                               2 (13.3)                                4 (12.1)                            4 (11.4) 
 ORR (CR + PR), n (%) [95% CI]†                    48 (60.0)                             46 (57.5)                             8 (53.3)                              18 (54.5)                         21 (60.0) 
                                                                                [48.4-70.9]                          [45.9-68.5]                         [26.6-78.7]                          [36.4-71.9]                      [42.1-76.1] 
 Median DoR (IRC), months (95% CI)       21.7 (21.7-NR)                    43.9 (26.1-NR)                    NR (1.8-NR)                       NR (5.8-NR)                   NR (5.8-NR) 
 Median PFS (IRC), months (95% CI)         12.1 (5.7-NR)                     11.6 (6.3-45.7)                     5.3 (0.9-NR)                        7.6 (2.7-NR)                    7.6 (2.7-NR) 
 Median OS, months (95% CI)                       NR (18.3-NR)                    33.5 (18.3-NR)                   13.8 (1.3-NR)                      15.5 (8.6-NR)                  15.5 (8.6-NR) 
*Non-evaluable patients had no valid post-baseline response assessments. †Using the two-sided 95% Clopper-Pearson exact method based on a binomial distribution. ‡One 
patient received tafasitamab only. ORR: objective response rate; CR: complete response; PR: partial response; 95% CI: 95% confidence interval; DoR: duration of response; IRC: 
independent review committee; PFS: progression-free survival; OS: overall survival; NR: not reached. 
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Figure 2. Proportion of patients 
in remission. (A-C) Kaplan-Meier 
plots of duration of response (A), 
progression-free survival. (B) and 
overall survival (C) after 35 
months of follow-up. 95% CI. 95% 
confidence interval; CR: complete 
response; DoR: duration of 
response; NE: not evaluable; NR: 
not reached; OS: overall survival; 
PD: progressive disease; PFS: pro-
gression-free survival; PR: partial 
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Figure 3. Kaplan-Meier esti-
mates of 30-month time-to-
event endpoints. (A) 
Duration of response,* (B) 
progression-free survival 
and (C) overall survival rates. 
*Based on patients who 
achieved an objective 
response (CR or PR) in the 
respective subgroups. 95% 
CI: 95% confidence interval; 
DoR: duration of response; 
IPI: International Prognostic 
Index; nC: number of 
patients censored; nE: num-
ber of patients with event; 
nR: number of patients at 
risk; n#: number of respon-
ders within each subgroup 
(A: DoR), or number of over-
all patients within each sub-
category (B: PFS; C: OS); OS: 
overall survival; PFS: pro-
gression-free survival. The 
vertical line indicates the 30-
month DoR (A), PFS (B) and 





There were no cases of grade ≥3 infusion-related reac-
tions, tumor lysis syndrome (of any grade), or cytokine 
release syndrome (of any grade) during the study. 
In total, 14 patients (17.3%) received blood transfusions 
during the study, and 37 patients (45.7%) received granu-
locyte colony-stimulating factor.  
The median duration of common adverse events (all 
grades) was longest for opportunistic infections12 (20 
days; 1 event each of progressive multifocal leukoen-
cephalopathy, grade 5; hepatitis B reactivation, grade 2; 
Clostridium difficile colitis, grade 2; and skin candida, grade 
1; 7 events of herpes viral infection, grade 1-4, including 1 
event of grade 4 disseminated varicella zoster virus infec-
tion in blood, gut, lungs and liver), followed by pneumo-
nia and fatigue or asthenia (18 and 15 days, respectively) 




The primary analysis of the L-MIND study, at a median 
follow-up of 13.2 months, showed that combination ther-
apy with tafasitamab and lenalidomide resulted in a 
promising response, including durable CR in a significant 
proportion of patients, and was well tolerated in trans-
plant-ineligible patients with R/R DLBCL.8 With follow-
up of at least 35 months, these long-term data confirm 
and extend the results of the primary analysis and provide 
more information on the consolidation tafasitamab 
monotherapy phase of the study, with an objective 
response rate of 57.5%. This regimen was granted accel-
erated approval by the US Food and Drug Administration 
for patients with R/R DLBCL not eligible for ASCT, based 
on a high response rate to therapy and prolonged DoR.13 
This long-term follow-up analysis shows clinically sig-
nificant durable responses for combination therapy fol-
lowed by tafasitamab monotherapy. The median DoR 
was nearly 44 months with a median OS of 33.5 months; 
neither the median DoR nor the median OS was reached 
in patients with a CR, with 80.1% and 81.3% of patients 
with a CR in response or alive at 36 months, respectively 
(Figure 2A, C). The median PFS was notable in patients 
who received tafasitamab plus lenalidomide as second-
line therapy compared with those who received the com-
bination third-line or later (23.5 months vs. 7.6 months 
[n=40, both groups]). The corresponding median OS were 
45.7 months vs. 15.5 months, suggesting that patients 
derive more benefit from this regimen when it is given in 
an earlier treatment setting. 
Good response rates were also achieved with combina-
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Table 3. Treatment-emergent adverse events occurring in ≥10% of 
patients, or grade 3-5 treatment-emergent adverse events in >1 
patient, reported at the updated L-MIND analysis. 
                                                   All grades (≥10%)              Grade ≥3 
                                                             n (%)                  (>1 patient) n (%) 
 Hematologic events 
     Neutropenia                                          41 (50.6)                           40 (49.4) 
     Anemia                                                    30 (37.0)                             6 (7.4) 
     Thrombocytopenia                               25 (30.9)                           14 (17.3) 
     Leukopenia                                            12 (14.8)                            9 (11.1) 
     Febrile neutropenia                            10 (12.3)                           10 (12.3) 
     Lymphopenia                                           6 (7.4)                               3 (3.7) 
 Non-hematologic events 
     Diarrhea                                                  29 (35.8)                             1 (1.2) 
     Asthenia                                                  20 (24.7)                             2 (2.5) 
     Cough                                                      22 (27.2)                             1 (1.2) 
     Peripheral edema                                19 (23.5)                                  0 
     Pyrexia                                                     19 (23.5)                             1 (1.2) 
     Decreased appetite                             18 (22.2)                                  0 
     Back pain                                                16 (19.8)                             2 (2.5) 
     Hypokalemia                                          15 (18.5)                             5 (6.2) 
     Fatigue                                                    14 (17.3)                             2 (2.5) 
     Constipation                                          14 (17.3)                                  0 
     Muscle spasms                                     12 (14.8)                                  0 
     Nausea                                                    12 (14.8)                                  0 
     Bronchitis                                               13 (16.0)                             1 (1.2) 
     Vomiting                                                  12 (14.8)                                  0 
     All infective pneumonia*                    10 (12.3)                             8 (9.9) 
     All urinary tract infection*                 10 (12.3)                             2 (2.5) 
     Dyspnea                                                  10 (12.3)                             1 (1.2) 
     C-reactive protein increased             9 (11.1)                                   0 
     Respiratory tract infection                  9 (11.1)                                   0 
     Upper respiratory tract infection       8 (9.9)                               2 (2.5) 
     Hypertension                                           7 (8.6)                               3 (3.7) 
*Defined by customized Medical Dictionary for Regulatory Activities (MedDRA) 
query. 
Table 4. Summary of hematologic and non-hematologic treatment-
emergent adverse events (any grade) by patient-years of exposure to 
tafasitamab. 
                                                                      N=81 
                                               Overall‡       Tafasitamab          Extended 
                                                                       plus              tafasitamab 
                                                                lenalidomide§      monotherapy¶ 
 Any TEAE, events/PYE                  13.95                 25.77                        6.64 
 Hematologic, events/PYE*                                                                           
     Neutropenia                                1.73                    3.79                         0.48 
     Anemia                                          0.58                    1.16                         0.22 
     Thrombocytopenia                    0.55                    1.39                         0.06 
     Leukopenia                                  0.44                    0.91                         0.14 
     Lymphopenia                               0.13                    0.30                         0.04 
     Febrile neutropenia                  0.06                    0.16                            0 
 Non-hematologic, events/PYE†                                                                   
     Diarrhea                                       0.51                    0.89                         0.28 
     Pyrexia                                          0.31                    0.48                         0.18 
     Asthenia                                       0.30                    0.52                         0.17 
     Peripheral edema                      0.29                    0.64                         0.08 
     Cough                                            0.24                    0.39                         0.17 
     Hypokalemia                                0.23                    0.52                         0.04 
     Fatigue                                          0.19                    0.39                         0.08 
     Nausea                                          0.18                    0.43                         0.03 
     Hypomagnesemia                      0.18                    0.27                         0.10 
     Constipation                                0.17                    0.36                         0.06 
     Bronchitis                                    0.17                    0.27                         0.11 
     Decreased appetite                  0.16                    0.32                         0.06 
     Respiratory tract infection      0.15                    0.14                         0.15 
     Hyperglycemia                            0.15                    0.09                         0.19 
Treatment-emergent adverse events (TEAE) were defined as any adverse event report-
ed in the following time interval (including the lower and upper limits): date of first 
administration of study treatment; date of last administration of study treatment + 30 
days, or if they were considered to be related to the study drug. The Medical 
Dictionary for Regulatory Activities (MedDRA) version 21.0 coding dictionary was 
used. *Threshold for hematologic TEAE: ≥0.05 events per patient-years of exposure 
(PYE).  †Threshold for non-hematologic TEAE: ≥0.15 events per PYE. ‡PYE was defined 
as the sum of duration of exposure for all patients, where duration of exposure was 
calculated as [(date of last dose of tafasitamab) – (date of first dose of tafasitamab) 
+ 1]/365.25.  §PYE was defined as the sum of duration of exposure for all patients, 
where duration of exposure was calculated as [(earliest date either study drug was 
discontinued) – (earliest date of administration of both study drugs) + 1]/365.25. 
Adverse event counts were for the combination treatment (tafasitamab + lenalido-
mide) period only.  ¶PYE was defined as the sum of duration of exposure for all 
patients, where duration of exposure was calculated as [(discontinuation date of taf-
asitamab) – (earliest date of tafasitamab infusion after lenalidomide discontinuation) 
+ 1]/365.25. Adverse event counts were for the tafasitamab monotherapy period only. 
tion therapy in the subgroups of patients with primary 
refractory, rituximab-refractory and last-therapy-refracto-
ry disease, especially given that these patients are consid-
ered difficult to treat, and those responses were durable. 
The median PFS and OS were, however, shorter than 
those for the overall population, especially in primary 
refractory patients, so there is still room for improvement 
in outcomes for difficult-to-treat patients. Notably, two 
patients with double- and triple-hit lymphoma and seven 
out of eight patients with transformed lymphoma 
responded to therapy. 
In the exploratory subgroup analysis, the only disease 
characteristic that appeared to have a negative effect on 
prognosis was IPI score ≥3 (i.e., intermediate-high- or 
high-risk disease); a high IPI score has long been recog-
nized as a risk factor for poor outcomes in DLBCL.14  
In regard to safety, there was little change in the 
adverse event profile since the primary analysis, which 
indicates a good tolerability profile for tafasitamab 
monotherapy. There was a reduction in the burden of 
common hematologic and non-hematologic adverse 
events as patients transitioned from combination therapy 
to tafasitamab monotherapy, with a residual tolerability 
profile similar to that in previous studies of tafasitamab 
monotherapy.10,11 This observation is of considerable 
importance for frail or elderly patients, who may prefer 
treatment with limited effects on their quality of life. In 
particular, the low incidence of infusion-related reactions 
(all of which were grade 1) and absence of cytokine 
release syndrome with tafasitamab plus lenalidomide is 
an important consideration for therapy in frail patients, 
given the occurrence of these events with CAR T-cell and 
other antibody therapies. 
Subsequent treatment, including ASCT and CAR T 
cells, was not precluded by previous administration of 
tafasitamab and lenalidomide in patients who experi-
enced disease progression during this combination regi-
men.  
In this trial, lenalidomide was given for a limited time 
of up to 12 months, which is in line with the median DoR 
of lenalidomide monotherapy in R/R non-Hodgkin lym-
phoma of 10.5 months,15,16 and the observation that the 
best responses with tafasitamab plus lenalidomide typi-
cally occur within this time window. Treatment until pro-
gression with tafasitamab is a novel concept, and 
although the exact contribution of the monotherapy 
phase cannot be delineated in this trial, it deserves further 
investigation. The excellent durability of CR achieved 
raises the question of whether cure is possible with tafa-
sitamab plus lenalidomide; longer follow-up data will be 
needed to assess this. 
Patients with R/R DLBCL who are not eligible for 
ASCT have few options. In patients who had previously 
received rituximab, cytotoxic chemotherapy with six to 
eight cycles of rituximab plus gemcitabine and oxaliplatin 
was associated with a CR/unconfirmed CR rate of 42% 
with a median PFS of 4 months and median OS of 8 
months, and an overall high incidence of grade ≥3 neu-
tropenia (73%) and thrombocytopenia (44%), requiring 
transfusions of blood (33%) and platelets (23%).17  
In patients with third- or later-line disease, the median 
PFS of 7.6 months and median OS of 15.5 months with 
tafasitamab plus lenalidomide are comparable with those 
achieved with other options such as polatuzumab plus 
bendamustine and rituxiamb (approved for R/R DLBCL 
in the European Union)7 and CAR T-cell therapy.6,18 The 
median DoR has not been reached, with more than 80% 
of patients with a best response of CR still in remission 
after 3.5 years. The L-MIND regimen is readily available 
to administer in an outpatient setting, with oral lenalido-
mide self-administered by the patient and weekly tafa-
sitamab infusions (fortnightly after the first 3 months of 
therapy).  
In conclusion, combination therapy with tafasitamab 
plus lenalidomide followed by tafasitamab monotherapy 
provided clinically significant durable responses in 
patients with R/R DLBCL who were not eligible for 
ASCT, including those with refractory disease, with man-
ageable toxicity during combination treatment and a 
reduced adverse event burden during tafasitamab 
monotherapy. These long-term data further validate tafa-
sitamab plus lenalidomide followed by extended tafasita-
mab monotherapy as a valuable option for patients with 
R/R DLBCL who are not eligible for ASCT. 
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